Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study

Miguel E. Aguado-Barrera; Carlos Lopez-Pleguezuelos; Antonio Gómez-Caamaño; Patricia Calvo-Crespo; Begoña Taboada-Valladares; David Azria; Pierre Boisselier; Erik Briers; Clara Chan; Jenny Chang-Claude; Carla Coedo-Costa; Ana Crujeiras-González; John J. Cuaron; Gilles Defraene; Rebecca M. Elliott; Corinne Faivre-Finn; Marzia Franceschini; Olivia Fuentes-Rios; Javier Galego-Carro; Sara Gutiérrez-Enríquez; Philipp Heumann; Daniel S. Higginson; Kerstie Johnson; Maarten Lambrecht; Philippe Lang; Yolande Lievens; Meritxell Mollà; Mónica Ramos; Tiziana Rancati; Tim Rattay; Andreas Rimner; Barry S. Rosenstein; Claudia Sangalli; Petra Seibold; Elena Sperk; Hilary Stobart; Paul Symonds; Christopher J. Talbot; Katrien Vandecasteele; Liv Veldeman; Tim Ward; Adam Webb; David Woolf; Dirk de Ruysscher; Catharine M.L. West; Ana Vega; REQUITE Consortium

doi:10.1016/j.lungcan.2024.108072

Retour

Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study

Article de revue

Avec comité de lecture

Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study

Miguel E. Aguado-Barrera, Carlos Lopez-Pleguezuelos, Antonio Gómez-Caamaño, Patricia Calvo-Crespo, Begoña Taboada-Valladares, David Azria, Pierre Boisselier, Erik Briers, Clara Chan, Jenny Chang-Claude, …

Lung cancer (Amsterdam, Netherlands), Vol.199, p.108072

01/01/2025

DOI: https://doi.org/10.1016/j.lungcan.2024.108072

PMID: 39740425

Résumé

Correlation measures

Fatigue

Lung cancer

Patient reported outcome measures

Quality of life

Radiation effects

Symptom assessment

•High concordance in evaluations of observable treatment-related symptoms.•Subjective symptoms like dyspnoea show notably lower agreement.•Factors like chemotherapy, COPD, and cancer stage linked to dyspnoea disagreement.•Impaired quality of life, notably fatigue, reduces symptom agreement.•Clinical factors and quality-of-life are crucial in lung cancer symptom assessment. We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet’s-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses. We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91). Our findings indicate strong alignment between healthcare professionals’ and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study
Créateurs - sans rôle: Miguel E. Aguado-Barrera - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Carlos Lopez-Pleguezuelos - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Antonio Gómez-Caamaño - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Patricia Calvo-Crespo - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Begoña Taboada-Valladares - Instituto de Investigación Sanitaria de Santiago
David Azria - Institut de Recherche en Cancérologie de Montpellier
Pierre Boisselier - Fédération Universitaire d’oncologie radiothérapie d’Occitanie Méditerranée, ICM, INSERM U1194 IRCM, Univ Montpellier, Montpellier, France
Erik Briers - Patient Advocat, Hasselt, Belgium
Clara Chan - Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom
Jenny Chang-Claude - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Carla Coedo-Costa - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Ana Crujeiras-González - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
John J. Cuaron - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Gilles Defraene - Department of Oncology, KU Leuven, Leuven, Belgium
Rebecca M. Elliott - University of Manchester
Corinne Faivre-Finn - Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom
Marzia Franceschini - Radiation Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Olivia Fuentes-Rios - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Javier Galego-Carro - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
Sara Gutiérrez-Enríquez - Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Philipp Heumann - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Daniel S. Higginson - Memorial Sloan Kettering Cancer Center
Kerstie Johnson - University of Leicester
Maarten Lambrecht - Radiation Oncology, KU Leuven, Leuven, Belgium
Philippe Lang - Fédération Universitaire d’oncologie radiothérapie d’Occitanie Méditerranée, ICG, CHU Caremeau, Nimes, France
Yolande Lievens - Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium
Meritxell Mollà - Vall d'Hebron Hospital Universitari
Mónica Ramos - Radiation Oncology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
Tiziana Rancati - Fondazione IRCCS Istituto Nazionale dei Tumori
Tim Rattay - University of Leicester
Andreas Rimner - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Barry S. Rosenstein - Icahn School of Medicine at Mount Sinai
Claudia Sangalli - Radiation Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Petra Seibold - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Elena Sperk - Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Hilary Stobart - Independent Cancer Patients’ Voice, United Kingdom
Paul Symonds - Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
Christopher J. Talbot - Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom
Katrien Vandecasteele - Ghent University, Ghent University Hospital, Ghent, Belgium
Liv Veldeman - Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium
Tim Ward - Trustee Pelvic Radiation Disease Association, NCRI CTRad Consumer, United Kingdom
Adam Webb - University of Leicester
David Woolf - Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom
Dirk de Ruysscher - Maastricht University
Catharine M.L. West - Translational Radiobiology Group, Division of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, United Kingdom
Ana Vega - Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
REQUITE Consortium
Détails de publication: Lung cancer (Amsterdam, Netherlands), Vol.199, p.108072
Éditeur: Elsevier B.V
Identifiants: 99140163709311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article